Jazz Pharmaceuticals to Participate in Wells Fargo Healthcare Conference

Jazz Pharmaceuticals will participate in the 2025 Wells Fargo Healthcare Conference, with management participating in a fireside chat on September 3, 2025. An audio webcast will be available on the company's website. Jazz Pharmaceuticals is a global biopharma company developing life-changing medicines for serious diseases with a diverse portfolio of marketed medicines and a growing pipeline of innovative therapeutics in oncology and neuroscience.

DUBLIN, Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its participation in the 2025 Wells Fargo Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, September 3, 2025, at 6:30 a.m. PDT / 9:30 p.m. EDT / 2:30 p.m. IST. An audio webcast of the event will be available on the company's investor relations website at [Investor Jazz Pharmaceuticals](https://investor.jazzpharma.com/investors/events-presentations).

Jazz Pharmaceuticals is a global biopharma company dedicated to developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options. The company's portfolio includes leading therapies for sleep disorders and epilepsy, and it has a growing pipeline of innovative therapeutics in oncology and neuroscience. Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with research and development laboratories, manufacturing facilities, and employees in multiple countries committed to serving patients worldwide [1].

In addition to its participation in the conference, Jazz Pharmaceuticals recently entered into an exclusive licensing agreement with Saniona. Under the terms of this agreement, Jazz will obtain exclusive worldwide rights to develop and commercialize SAN2355, a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator in preclinical development for epilepsy and other potential indications [2]. This collaboration leverages Jazz's expertise in epilepsy and neuroscience, positioning SAN2355 as a promising option for epilepsy and neurological conditions.

The fireside chat at the 2025 Wells Fargo Healthcare Conference will provide investors and financial professionals with an opportunity to hear directly from Jazz Pharmaceuticals' management about the company's latest developments, including its pipeline of innovative therapeutics and its strategic collaborations. The webcast will be archived on the company's website for 30 days following the event.

References:
[1] https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-the-2025-wells-fargo-healthcare-conference-302533954.html
[2] https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-enters-exclusive-licensing-agreement